Anebulo Pharmaceuticals Inc (ANEB) Stock Price

2.26 ▼ -0.11 (-4.64%)
Open: 2.38 Vol: 7.74K Day's range: 2.24 - 2.38 Dec 05, 16:00 EST
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
ANEB Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL SELL SELL SELL SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 2.31▼ 2.31▼ 2.31▼ 2.34▼ 2.33▼
MA10 2.33▼ 2.34▼ 2.34▼ 2.36▼ 2.43▼
MA20 2.36▼ 2.38▼ 2.37▼ 2.35▼ 2.50▼
MA50 2.43▼ 2.49▼ 2.51▼ 2.46▼ 1.81▲
MA100 2.55▼ 2.49▼ 2.48▼ 2.48▼ 2.03▲
MA200 2.49▼ 2.46▼ 2.47▼ 1.87▲ 2.64▼
  5 mins 30 mins Hourly Daily Weekly
MACD -0.004▼ -0.002▼ -0.002▼ 0.000▼ -0.060▼
RSI 42.714▼ 42.583▼ 42.617▼ 39.859▼ 51.053▲
STOCH 27.026     27.464     27.464     41.154     33.262    
WILL %R -85.714▼ -85.714▼ -85.714▼ -82.143▼ -54.630    
CCI -97.596     -94.949     -94.949     -98.542     -77.719    
Latest Filters Detected On ANEB
▼ MACD $ANEB MACD(12,26,9) Crossed Below Signal Line Set Alert
MA $ANEB Price Crossed Below MA(13) Set Alert
▼ BREAK $ANEB Price Breaks 10 Days Low Set Alert
CDL $ANEB Evening Star Candlestick Pattern Detected Set Alert
CDL $ANEB Engulfing Candlestick Pattern Detected Set Alert
Anebulo Pharmaceuticals Inc News
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates
Wednesday, November 12, 2025 04:00 PM
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or ...
Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity
Thursday, September 25, 2025 12:30 AM
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the “Company” or ...
Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity
Wednesday, September 24, 2025 09:31 PM
Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity Anebulo Pharmaceuticals, ...
ANEB historical stock data
date open high low close volume
05/12/25 2.38 2.38 2.24 2.26 7,739
04/12/25 2.37 2.37 2.2613 2.37 1,161
03/12/25 2.2601 2.33 2.2601 2.33 1,804
02/12/25 2.40 2.41 2.35 2.38 3,660
01/12/25 2.34 2.39 2.28 2.36 6,117
28/11/25 2.405 2.405 2.34 2.34 2,600
26/11/25 2.47 2.47 2.33 2.34 149,712
25/11/25 2.45 2.49 2.45 2.49 4,266
24/11/25 2.2701 2.408 2.2701 2.3664 5,718
21/11/25 2.3683 2.3683 2.355 2.355 2,495
Quote Details
52wk Low:0.80
52wk High:3.42
Vol:7.74K
Avg Vol(3m):300.5K
1Y Chng:+128.28%
1M Chng:-17.82%
Add to Watch List
More Information
Index US Composite
Market Cap. 97.37M